Short‐term serious adverse events (SAEs) · adults undergoing intra‐ and transperitoneal laparoscopic procedures
It is very uncertain whether summary of findings table ‐ Deep neuromuscular blockade (NMB) changes short‐term serious adverse events (SAEs) compared with shallow NMB (very low certainty).
1 finding from 1 review
Adverse events associated with treatment · Adults with oropharyngeal cancer
1 finding from 1 review
Adverse events: grade 2+ treatment-related events similar (31/34 radiotherapy vs 33/34 surgery; RR 0.94, 0.83 to 1.06); more hearing loss/neutropenia/constipation/tinnitus with radiotherapy, more oral bleeding/trismus…
1 study · 68 participants
Very low
Adverse events associated with treatment · Adults with oral cavity cancer (tongue or floor of mouth) and clinically negative neck nodes
Elective neck dissection (at time of primary tumour resection) probably leads to higher adverse events associated with treatment compared with therapeutic (delayed) neck dissection (moderate certainty).
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity cancer
1 finding from 1 review
Adverse events (BHNCSG 1998): flap necrosis, wound infection, fistula, vascular rupture, haematoma, seroma, chyle fistula; no complications in 45/76 modified radical ND and 54/72 supraomohyoid ND; 2 vs 1 postoperative…
1 study · 148 participants
Low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
The review found no eligible studies for this question.
1 finding from 1 review
Serious adverse events at 6 or 12 months · adults and children with strabismus
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events in infants ‐ not measured · GORD in infants
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Anxiety (adverse effect, post‐intervention) · adults (aged 16 years and over) with CF
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events associated with treatment · Adults with oral cavity cancer (tongue or floor of mouth) and clinically negative neck nodes
1 finding from 1 review
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: significant difference in complication rates, lower for supraomohyoid (SOND 13.0% vs MRND 21.9%, P=0.040). UW-QOL at 1 year: supraomohyoid superior in pain relief (78.8% vs 75.2%, P=0.013) and shoulder…
1 study · 332 participants
Very low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer
1 finding from 1 review
Adverse events: severe acute effects in both groups (subcutaneous fibrosis, telangiectasia, moderate-to-severe oedema, xerostomia, trismus, dysphagia); subcutaneous fibrosis more prevalent with surgery + radiotherapy…
1 study · 35 participants
Very low
Adverse events associated with treatment · Adults with oral cavity or oropharyngeal cancer with nodal disease (stage N2 or N3)
1 finding from 1 review
Adverse events 12 months postintervention · people who smoke
Heated tobacco use showed no clear difference in adverse events – measured by self‐report compared with cigarette smoking (low certainty).
1 finding from 1 review
Adverse events 12 months postintervention · people who smoke
It is very uncertain whether heated tobacco use changes adverse events – measured by self‐report compared with snus use (very low certainty).
1 finding from 1 review
Adverse events 12 months postintervention · people who smoke
It is very uncertain whether heated tobacco use changes adverse events – measured by self‐report compared with abstinence from tobacco (very low certainty).
1 finding from 1 review
Adverse events during treatment period · symptomatic people with COVID‐19
It is very uncertain whether fluvoxamine plus standard care changes any adverse events (during study period) compared with placebo plus standard care (very low certainty).
1 finding from 1 review
Adverse events ‐ malignancy at 36 months · primary membranous nephropathy in adults with nephrotic syndrome
It is very uncertain whether calcineurin inhibitors ± steroids changes adverse events ‐ malignancy at 36 months compared with placebo/no treatment/supportive treatment/steroids (very low certainty).
1 finding from 1 review
Participants with serious adverse events · people who have been exposed to SARS‐CoV‐2
1 finding from 1 review
Participants with serious adverse events · adults with mild to severe COVID‐19
Hydroxychloroquine (HCQ) showed no clear difference in participants with serious adverse events compared with standard care or placebo (low certainty).
1 finding from 1 review